Been follwing Biosign
Technologies BIO.v They are taking iniative in marketing their products and seem to be doing well. This potentially a big winner. Management are also promoting the company. I expect these shares to move up currently at .04
Biosign Investor Conference Call scheduled
TORONTO, July 5, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") made the following announcements:
Biosign Schedules Investor Conference Call
Biosign is pleased to announce an Investor Conference Call, scheduled for Monday, July 15th, 2013 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared statement commenting on recent news releases and placing those releases into the context of the Company's business plan. Following this presentation, Mr. Kaul will answer a number of questions submitted in advance in writing, regarding the business of the Company.
The conference call is open to any investor or stakeholder, including shareholders, broker-dealers and other securities professionals. The call will be recorded and available for review at biosign.com. To submit one or more questions to the CEO, please email your question to ceo@biosign.com with the words "Investor Question for Conference Call" in the subject line. Biosign management will endeavour to address as many questions as possible in the one-hour allocated to the call. To participate in the call, please use the following login credentials:
Dial-In Number: 877-394-5901 Participant Code: 2169148
Biosign CEO Robert Kaul stated, "In the last several weeks, Biosign has made a number of material announcements related to our business plan. Management is pleased to be able to communicate with investors and other interested parties in order to place these announcements into greater context, and to address various stakeholder inquiries."
Biosign Partially Converts Debenture
The Company has received and processed a "Notice of Election to Convert" a portion of the Debenture issued to BioAnalytics Inc. under the terms of the Asset Purchase Agreement between the parties dated December 7th, 2012. BioAnalytics has converted $240,000 out of a total balance of $300,000 into 2,000,000 common shares of Biosign. The shares issued are subject to a four-month and one day hold period under applicable TSX-V regulations.
Completion of Shares for Debt Transaction - Update
On June 11th, 2013, the Company previously announced that it has entered into agreements to convert $205,660 of indebtedness into 4,113,200 common shares of the Company at a price of $0.05 per share. The Company wishes to advise that such shares issued under this conversion are subject to a four-month and one day hold period under applicable securities laws.
Biosign CEO Robert Kaul commented: "These conversions of debt into equity are a welcome endorsement of Biosign's ability to execute our business plan. We note in particular that such conversions were completed at a premium to the current market price".
About Biosign Technologies Inc:
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled health information products. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for clinical decision support, self-care, wellness and disease management, while its Healthanywhere™ software suite offers industry-leading remote patient monitoring solutions. The Company offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Dentist. For more information on Biosign, please visit www.biosign.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
Contact Information for Biosign:
Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: (416) 218-9800 ext. 201
Email: ceo@biosign.com
Copyright CNW Group 2013
Canada Newswire
July 5, 2013 - 3:08 PM EDT
|
